Fierce Healthcare June 21, 2022
LAS VEGAS—Stemming the tide of rising drug prices will require bringing all the major players to the table, experts said Tuesday.
David Holmberg, CEO of Highmark Health, said health insurers want to approve every new therapy that hits the market, but drug companies need to meet payers halfway in finding ways to address climbing expenses.
For example, he said, look at the release of a hypothetical upgrade to an MRI machine. The new device improves accuracy by 5% but costs 25% more than earlier models. This is a clear mismatch, Holmberg said.
Incentives from the healthcare system should push drugmakers to develop cutting-edge therapies, but there also must be “agreement on what...
Today's Sponsors
Today's Sponsor